The company's total income from operations however declined to Rs 3,783 crore during the fourth quarter, ...More

The company's total income from operations however declined to Rs 3,783 crore during the fourth quarter, as compared to Rs 3,846 crore in the corresponding period of FY20, Lupin Ltd said in a statement. ...Less

Lupin reported a 52% YoY growth in net profit to Rs 368 crore for March 2024 quarter. Revenue increased b ...More

Lupin reported a 52% YoY growth in net profit to Rs 368 crore for March 2024 quarter. Revenue increased by 12% to Rs 4,961 crore. The company declared a dividend of Rs 8 per share. ...Less

The company reported a consolidated net profit of Rs 547 crore in , down 1.1 per cent, as compared to a n ...More

The company reported a consolidated net profit of Rs 547 crore in , down 1.1 per cent, as compared to a net profit of Rs 553 crore in the corresponding quarter. ...Less

Lupin's shares reached a 52-week high of INR 830.3 after it announced the launch of its Darunavir Tablets ...More

Lupin's shares reached a 52-week high of INR 830.3 after it announced the launch of its Darunavir Tablets to market a generic equivalent of Janssen Products' Prezista Tablets. The estimated annual sales of Darunavir Tablets in the US is at around $308m (as of IQVIA MAT March 2023). Lupin also reported a surge in stock figures, having gained over 16% in a month and over 35% in a year. Furthermore, the stock's day RSI (14) is at 79.8 and MACD is at 24.7, indicating bullish signals. ...Less

Consolidated income from operations of the company stood at Rs 3,791 crore for the quarter under consider ...More

Consolidated income from operations of the company stood at Rs 3,791 crore for the quarter under consideration as against Rs 3,807.02 crore for the same period year ago. ...Less

Lupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferie ...More

Lupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferies, Kotak, and Bernstein maintained a reduce, underperform, and market-perform rating, respectively, on the stock. Jefferies found the gSpiriva approval positive but widely anticipated and indicated an expensive PE valuation. While Kotak believes gSpiriva's upside is priced in, it stays cautious given Lupin's weak execution record and subpar margin practice. Additionally, Bernstein stated that Lupin is trading higher than Sun Pharma. ...Less

Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as aga ...More

Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year. ...Less

The fall in the index was led by losses in HDFC, ITC, Infosys, HDFC Bank, and NTPC. The Nifty50 was tradi ...More

The fall in the index was led by losses in HDFC, ITC, Infosys, HDFC Bank, and NTPC. The Nifty50 was trading above its crucial support level of 7,000. ...Less